Sonar Soni Panigoro , Arga Patrianagara , Ninik Sukartini , Trevino Aristarkus Pakasi , Samuel Johny Haryono
{"title":"炎症指标作为接受新辅助化疗（NAC）的局部晚期乳腺癌（LABC）患者临床反应的预后因素","authors":"Sonar Soni Panigoro , Arga Patrianagara , Ninik Sukartini , Trevino Aristarkus Pakasi , Samuel Johny Haryono","doi":"10.1016/j.senol.2023.100553","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p><span><span>Breast cancer is a prevalent and fatal cancer worldwide. Neoadjuvant chemotherapy<span> is a treatment option used to reduce tumor size </span></span>in patients with </span>locally advanced breast cancer<span>. The neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), and platelet–lymphocyte ratio (PLR) are inflammatory markers that have been studied as prognostic factors in breast cancer. This cross-sectional study aimed to investigate the role of NLR, LMR, and PLR in the clinical response to neoadjuvant chemotherapy in women with locally advanced breast cancer.</span></p></div><div><h3>Materials and methods</h3><p>We used a cross-sectional research design for this study with the aim of observing the relation between NLR, LMR, and PLR and the clinical response of neoadjuvant chemotherapy. The study was conducted in Cipto Mangunkusumo General Hospital. We analyzed the medical records of 84 patients treated with neoadjuvant chemotherapy between 2016 and 2021.</p></div><div><h3>Results</h3><p><span>Our study found that majority of the subjects receives CAF combination of NAC with inoperable breast cancer. Most of the subjects have luminal B type of breast cancer and no clinical response to chemotherapy regimen. Surgery has significant association with clinical response in patients receiving NAC (</span><em>P</em> = <.001). There are no significant correlation between NLR, LMR, and PLR with clinical response to neoadjuvant chemotherapy. However, we did observe a significant association between NLR and 1-year mortality rate.</p></div><div><h3>Conclusion</h3><p>In conclusion, significant association between NLR and 1-year morality rate suggest that NLR may serve as a useful prognostic factor in breast cancer patients receiving neoadjuvant chemotherapy.</p></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"37 1","pages":"Article 100553"},"PeriodicalIF":0.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Inflammatory indicators as a prognostic factor of clinical response in locally advanced breast cancer (LABC) patients receiving neoadjuvant chemotherapy (NAC)\",\"authors\":\"Sonar Soni Panigoro , Arga Patrianagara , Ninik Sukartini , Trevino Aristarkus Pakasi , Samuel Johny Haryono\",\"doi\":\"10.1016/j.senol.2023.100553\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p><span><span>Breast cancer is a prevalent and fatal cancer worldwide. Neoadjuvant chemotherapy<span> is a treatment option used to reduce tumor size </span></span>in patients with </span>locally advanced breast cancer<span>. The neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), and platelet–lymphocyte ratio (PLR) are inflammatory markers that have been studied as prognostic factors in breast cancer. This cross-sectional study aimed to investigate the role of NLR, LMR, and PLR in the clinical response to neoadjuvant chemotherapy in women with locally advanced breast cancer.</span></p></div><div><h3>Materials and methods</h3><p>We used a cross-sectional research design for this study with the aim of observing the relation between NLR, LMR, and PLR and the clinical response of neoadjuvant chemotherapy. The study was conducted in Cipto Mangunkusumo General Hospital. We analyzed the medical records of 84 patients treated with neoadjuvant chemotherapy between 2016 and 2021.</p></div><div><h3>Results</h3><p><span>Our study found that majority of the subjects receives CAF combination of NAC with inoperable breast cancer. Most of the subjects have luminal B type of breast cancer and no clinical response to chemotherapy regimen. Surgery has significant association with clinical response in patients receiving NAC (</span><em>P</em> = <.001). There are no significant correlation between NLR, LMR, and PLR with clinical response to neoadjuvant chemotherapy. However, we did observe a significant association between NLR and 1-year mortality rate.</p></div><div><h3>Conclusion</h3><p>In conclusion, significant association between NLR and 1-year morality rate suggest that NLR may serve as a useful prognostic factor in breast cancer patients receiving neoadjuvant chemotherapy.</p></div>\",\"PeriodicalId\":38058,\"journal\":{\"name\":\"Revista de Senologia y Patologia Mamaria\",\"volume\":\"37 1\",\"pages\":\"Article 100553\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista de Senologia y Patologia Mamaria\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0214158223000853\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de Senologia y Patologia Mamaria","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0214158223000853","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Inflammatory indicators as a prognostic factor of clinical response in locally advanced breast cancer (LABC) patients receiving neoadjuvant chemotherapy (NAC)
Objectives
Breast cancer is a prevalent and fatal cancer worldwide. Neoadjuvant chemotherapy is a treatment option used to reduce tumor size in patients with locally advanced breast cancer. The neutrophil–lymphocyte ratio (NLR), lymphocyte–monocyte ratio (LMR), and platelet–lymphocyte ratio (PLR) are inflammatory markers that have been studied as prognostic factors in breast cancer. This cross-sectional study aimed to investigate the role of NLR, LMR, and PLR in the clinical response to neoadjuvant chemotherapy in women with locally advanced breast cancer.
Materials and methods
We used a cross-sectional research design for this study with the aim of observing the relation between NLR, LMR, and PLR and the clinical response of neoadjuvant chemotherapy. The study was conducted in Cipto Mangunkusumo General Hospital. We analyzed the medical records of 84 patients treated with neoadjuvant chemotherapy between 2016 and 2021.
Results
Our study found that majority of the subjects receives CAF combination of NAC with inoperable breast cancer. Most of the subjects have luminal B type of breast cancer and no clinical response to chemotherapy regimen. Surgery has significant association with clinical response in patients receiving NAC (P = <.001). There are no significant correlation between NLR, LMR, and PLR with clinical response to neoadjuvant chemotherapy. However, we did observe a significant association between NLR and 1-year mortality rate.
Conclusion
In conclusion, significant association between NLR and 1-year morality rate suggest that NLR may serve as a useful prognostic factor in breast cancer patients receiving neoadjuvant chemotherapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
